COJ0 Stock Overview
Engages in the development of gene therapy for severe life-altering diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CombiGene AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.17 |
| 52 Week High | SEK 0.34 |
| 52 Week Low | SEK 0.077 |
| Beta | 1.53 |
| 11 Month Change | -9.21% |
| 3 Month Change | -13.32% |
| 1 Year Change | -7.95% |
| 33 Year Change | -84.82% |
| 5 Year Change | n/a |
| Change since IPO | -77.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| COJ0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.2% | -0.7% | 0.2% |
| 1Y | -8.0% | -17.2% | 8.5% |
Return vs Industry: COJ0 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: COJ0 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| COJ0 volatility | |
|---|---|
| COJ0 Average Weekly Movement | 23.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: COJ0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: COJ0's weekly volatility has increased from 16% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 9 | Peter Ekolind | www.combigene.com |
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures.
CombiGene AB (publ) Fundamentals Summary
| COJ0 fundamental statistics | |
|---|---|
| Market cap | €4.41m |
| Earnings (TTM) | -€3.22m |
| Revenue (TTM) | €273.48k |
16.1x
P/S Ratio-1.4x
P/E RatioIs COJ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COJ0 income statement (TTM) | |
|---|---|
| Revenue | SEK 3.15m |
| Cost of Revenue | SEK 22.01m |
| Gross Profit | -SEK 18.86m |
| Other Expenses | SEK 18.22m |
| Earnings | -SEK 37.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -1.87 |
| Gross Margin | -599.71% |
| Net Profit Margin | -1,179.02% |
| Debt/Equity Ratio | 0% |
How did COJ0 perform over the long term?
See historical performance and comparison